Survival based on humane end points was tracked, witha 1.7- and 1.2-fold increase in median survival with 4-1BBL/IL-12or 4-1BBL/IL-12/IFNγ NPs with anti-PD1 compared to control,indicating significantly improved survival with either treatment (adjusted p = 0.0005 and 0.03, respectively) (Figure 6D), while anti-PD1 alone had no significanteffect on tumor growth and mouse survival (Figure 6C,D). The gene discussed is IFNG; the disease is neoplasm.